Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. De Boulle is active.

Publication


Featured researches published by K. De Boulle.


American Journal of Medical Genetics | 1996

Long-term potentiation in the hippocampus of fragile X knockout mice.

Jean-Marie Godfraind; Edwin Reyniers; K. De Boulle; Rudi D'Hooge; P.P. De Deyn; Cathy E. Bakker; Ben A. Oostra; R.F. Kooy; P.J. Willems

To gain more insight in the physiological function of the fragile X gene (FMR1) and the mechanisms leading to fragile X syndrome, the Fmr1 gene has been inactivated in mice by gene targeting techniques. In the Morris water maze test, the Fmr1 knockout mice learn to find the hidden platform nearly as well as the control animals, but show impaired performance after the position of the platform has been modified. As malperformance in the Morris water maze test has been associated with impaired long-term potentiation (LTP), electrophysiological studies were performed in hippocampal slices of Fmr1 knockout mice to check for the presence of LTP. Judged by field extracellular excitatory postsynaptic potential recordings in the CA1 hippocampal area, Fmr1 knockout mice express LTP to a similar extent as their wild type littermates during the first 1-2 hr after high frequency stimulation. Also, short-term potentiation (STP) was similar in both types of mice. To investigate whether Fmr1 is involved in the latter stages of LTP as an immediate early gene, we compared Fmr1 mRNA quantities on northern blots after chemical induction of seizures. A transient increase in the transcription of immediate early genes is thought to be essential for the maintenance of LTP. As no increase in Fmr1 mRNA could be detected, neither in cortex nor in total brain, during the first 2 1/2 hr after pentylenetetrazol-induced seizures, it is unlikely that Fmr1 is an immediate early gene in mice. In conclusion, we found no evidence for a function of FMR1 in STP or LTP.


American Journal of Human Genetics | 1998

Mutations in the EXT1 and EXT2 Genes in Hereditary Multiple Exostoses

Wim Wuyts; W. Van Hul; K. De Boulle; Jan Hendrickx; E. Bakker; Filip Vanhoenacker; F. Mollica; Hermann-Josef Lüdecke; B.S. Sayli; U.E. Pazzaglia; Geert Mortier; B.C.J. Hamel; E.U. Conrad; Mark Matsushita; Wendy H. Raskind; P.J. Willems

Hereditary multiple exostoses (EXT; MIM 133700) is an autosomal dominant bone disorder characterized by the presence of multiple benign cartilage-capped tumors (exostoses). Besides suffering complications caused by the pressure of these exostoses on the surrounding tissues, EXT patients are at an increased risk for malignant chondrosarcoma, which may develop from an exostosis. EXT is genetically heterogeneous, and three loci have been identified so far: EXT1, on chromosome 8q23-q24; EXT2, on 11p11-p12; and EXT3, on the short arm of chromosome 19. The EXT1 and EXT2 genes were cloned recently, and they were shown to be homologous. We have now analyzed the EXT1 and EXT2 genes, in 26 EXT families originating from nine countries, to identify the underlying disease-causing mutation. Of the 26 families, 10 families had an EXT1 mutation, and 10 had an EXT2 mutation. Twelve of these mutations have never been described before. In addition, we have reviewed all EXT1 and EXT2 mutations reported so far, to determine the nature, frequency, and distribution of mutations that cause EXT. From this analysis, we conclude that mutations in either the EXT1 or the EXT2 gene are responsible for the majority of EXT cases. Most of the mutations in EXT1 and EXT2 cause premature termination of the EXT proteins, whereas missense mutations are rare. The development is thus mainly due to loss of function of the EXT genes, consistent with the hypothesis that the EXT genes have a tumor- suppressor function.


Cytogenetic and Genome Research | 1999

Refined physical mapping and genomic structure of the EXTL1 gene

Wim Wuyts; Nicole Spieker; N. Van Roy; K. De Boulle; A. De Paepe; P.J. Willems; W. Van Hul; Rogier Versteeg; F. Speleman

Recently, the EXTL1 gene, a member of the EXT tumor suppressor gene family, has been mapped to 1p36, a chromosome region which is frequently implicated in a wide variety of malignancies, including breast carcinoma, colorectal cancer and neuroblastoma. In this study, we show that the EXTL1 gene is located between the genetic markers D1S511 and D1S234 within 200 kb of the LAP18 gene on chromosome 1p36.1, a region which has been proposed to harbor a tumor suppressor gene implicated in MYCN-amplified neuroblastomas. In addition, we determined the genomic structure of the EXTL1 gene, revealing that the EXTL1 coding sequence spans 11 exons within a 50-kb region.


Human Genetics | 1993

An EcoRI RFLP in the 5' region of the human NF1 gene

Edwin Reyniers; K. De Boulle; Douglas A. Marchuk; Lone B. Andersen; Francis S. Collins; P.J. Willems

Von Recklinghausen neurofibromatosis or type l neurofibromatosis (NF1), is one of the most common autosomal dominant disorders. NF1 is characterized by neurofibromas, café-au-lait spots and Lisch nodules of the iris. The NF1 gene is located in 17q11.2. The restriction fragment length polymorphism reported here will be useful in linkage analysis in NF1 families.


Journal of The European Academy of Dermatology and Venereology | 2001

Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature: Prevalence of superficial fungal infections among sports-active individuals

R Caputo; K. De Boulle; J.Q. Del Rosso; R Nowicki

To examine the effect of sport activities on the prevalence of foot disease in the Achilles survey, conducted during the spring of 1997 and 1998 in several European countries.


Human Molecular Genetics | 1996

Positional Cloning of a Gene Involved in Hereditary Multiple Exostoses

Wim Wuyts; W. Van Hul; Jan Wauters; M. Nemtsova; Edwin Reyniers; E Van Hul; K. De Boulle; B. de Vries; Jan Hendrickx; I. Herrygers; Paul Bossuyt; Wendy Balemans; Erik Fransen; Lieve Vits; Paul Coucke; Norma J. Nowak; Thomas B. Shows; L. Mallet; A. van den Ouweland; Julie McGaughran; D. J. J. Halley; P.J. Willems


Human Molecular Genetics | 1993

Alternative splicing in the fragile X gene FMR1

Annemieke J. M. H. Verkerk; E. de Graaff; K. De Boulle; Evan E. Eichler; D.S. Konecki; Edwin Reyniers; A. Manca; Annemarie Poustka; P.J. Willems; David L. Nelson; Ben A. Oostra


European Journal of Human Genetics | 1997

Identification and characterization of a novel member of the EXT gene family, EXTL2.

Wim Wuyts; W. Van Hul; Jan Hendrickx; F. Speleman; Jan Wauters; K. De Boulle; N. Van Roy; T. van Agtmael; Paul Bossuyt; P.J. Willems


Journal of The European Academy of Dermatology and Venereology | 2001

Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature.

R Caputo; K. De Boulle; J.Q. Del Rosso; R Nowicki


Journal of The European Academy of Dermatology and Venereology | 2000

Melanoma screening: results of the first one-day campaign in Belgium ('melanoma Monday').

M. Vandaele; B Richert; J van der Endt; B Boyden; Lieve Brochez; Del Marmol; K. De Boulle; Maria Garmyn; M Laporte; I Maselis; C. Pirard; D Roseeuw; M Schramme; I Tromme

Collaboration


Dive into the K. De Boulle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wim Wuyts

University of Antwerp

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ben A. Oostra

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

N. Van Roy

Ghent University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge